• Stromal cells in the hematopoietic niche
  S Mendez Ferrer (United Kingdom)
• Diversity of stromal cells in the skin
  F Watt (United Kingdom)
• The role of mesenchymal inflammation in leukemia evolution
  M Raaijmakers (The Netherlands)

• 1.1. Gene network analysis of the hematopoietic stem/progenitor cell-supportive bone marrow mesenchymal stromal cells
  P Charbord (France)
• 1.2. The transcriptional landscape of the Aorta-Gonad-Mesonephros hematopoietic microenvironment
  C Durand (France)
• 1.3. Impairment in the mesenchymal stromal cell niche of Beta-thalassemia patients: implications of prolonged iron exposure
  M Bernardo (Italy)
• 1.4. Differential RNA expression profile of human bone marrow mesenchymal stromal cells after in vitro expansion in clinical grade human platelet lysate versus fetal calf serum
  A De Becker (Belgium)
• 1.5. Mesenchymal stromal cells induce a permissive state in the bone marrow that enhances G-CSF-induced mobilization in mice
  M van Pel (The Netherlands)
• 1.6. Ex vivo fucosylation of adipose mesenchymal stem cells improves their prophylactic efficacy in murine acute graft-versus-host disease
  JE Millán-Rivero (Spain)
• 1.7. Changes In MSCs characteristics after interaction With lymphocytes do not depend on their compatibility
  NA Petinati (Russia)

17:30 - 18:00 ABSTRACT SESSION

Clinical and Regulatory Aspects

Chair: F Dazzi (United Kingdom)

• 2.1. Excellent response and low mortality in 69 patients with severe steroid and therapy-refractory agvhd after treatment with mesenchymal stromal cells generated from pooled bone marrow mononuclear cells of multiple donors (MSC-FFM)
  S Kuci (Germany)
• 2.2. The international phase III MSC trial challenge
  LEM Oosten (The Netherlands)

18:00 - 19:00 Welcome reception

Friday, November 24, 2017

09:00 - 10:30 SCIENTIFIC SESSION

MSC and the tumor microenvironment

Chair: Y Shi (China)

• Stromal function in the evolving tumor microenvironment: a role in immune modulation?
  J Shields (United Kingdom)
• Ontogeny and function of tumor-associated macrophages
  T Lawrence (France)
• Role of myeloid-derived suppressor cells in cancer immune evasion
  V Bronte (Italy)

10:30 - 11:00 Coffee break

11:00 - 12:30 SCIENTIFIC SESSION

Product development

Chair: WE Fibbe (The Netherlands)

• MSCs and tissue immune microenvironment
  Y Shi (China)
• Potency assays development
  K Schepers (The Netherlands)
• Mechanism-based biomarker to predict clinical response
  A Galleu (United Kingdom)

12:30 - 13:30 Lunch

13:30 - 15:30 SCIENTIFIC SESSION

Clinical trials

Chair: K Le Blanc (Sweden)

• Allogeneic adipose-derived MSC for complex perianal fistulas in Crohn’s disease 
  D Garcia-Olmo (Spain)
• Mesenchymal stromal cells in kidney transplantation: Lessons learned from initial trials
  AJ Rabelink (The Netherlands)
• Mesenchymal stromal cells for Graft-versus-Host Disease
  M Bornhäuser (Germany)
• Mesenchymal stromal cells in therapeutic perspective
  WE Fibbe (The Netherlands)

15:30 - 16:00 Coffee break

16:00 - 17:00 ABSTRACT SESSION

Biology and mechanisms of action

Chair: AJ Rabelink (The Netherlands)

• 3.1. Immunomodulation induced by Mesenchymal stem cells (MSC) is triggered through phagocytosis of MSC by innate immune cells
  SFH de Witte (The Netherlands)
• 3.2. High-throughput, non-perturbing quantification of mesenchymal stroll cell adipocytic differentiation using Digital Holographic Microscopy
  O Naveiras (Switzerland)
• 3.3. Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes
  A Merino (The Netherlands)
• 3.4. Mesenchymal stem cell genetically engineered to express alpha-1 anti-trypsin show superior efficacy in humanized graft-vs-host-disease model in comparison to native mesenchymal stem cells
  FGH Hermann (Germany)
• 3.5. The phenotype and role of bone marrow mesenchymal stem and progenitor cells in chronic myeloid leukemia
  M Dolinska (Sweden)
• 3.6. Low-dose irradiation of mesenchymal stromal cell alters they Adipogenic/Osteogenic differentiation capacity improving their hematopoietic-supporting ability
  S Preciado (Spain)

17:00 - 17:30 INTERACTIVE PANEL DISCUSSION

Towards MSC as a standard of care, where do we stand?

Chair: AJ Rabelink (The Netherlands)

Panelists:

• FPL Luyten (Belgium)
• K Le Blanc (Sweden)
• F Sánchez-Guijo (Spain)